These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30350309)

  • 1. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
    Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
    Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
    Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
    Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.
    Lee DD; Leão R; Komosa M; Gallo M; Zhang CH; Lipman T; Remke M; Heidari A; Nunes NM; Apolónio JD; Price AJ; De Mello RA; Dias JS; Huntsman D; Hermanns T; Wild PJ; Vanner R; Zadeh G; Karamchandani J; Das S; Taylor MD; Hawkins CE; Wasserman JD; Figueiredo A; Hamilton RJ; Minden MD; Wani K; Diplas B; Yan H; Aldape K; Akbari MR; Danesh A; Pugh TJ; Dirks PB; Castelo-Branco P; Tabori U
    J Clin Invest; 2019 Jan; 129(1):223-229. PubMed ID: 30358567
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Batista R; Lima L; Vinagre J; Pinto V; Lyra J; Máximo V; Santos L; Soares P
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.
    Castelo-Branco P; Leão R; Lipman T; Campbell B; Lee D; Price A; Zhang C; Heidari A; Stephens D; Boerno S; Coelho H; Gomes A; Domingos C; Apolonio JD; Schäfer G; Bristow RG; Schweiger MR; Hamilton R; Zlotta A; Figueiredo A; Klocker H; Sültmann H; Tabori U
    Oncotarget; 2016 Sep; 7(36):57726-57736. PubMed ID: 27437772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive behavioural assessment of TERT in bladder cancer.
    El Azzouzi M; El Ahanidi H; Hassan I; Tetou M; Ameur A; Bensaid M; Al Bouzidi A; Oukabli M; Alaoui CH; Addoum B; Chaoui I; Benbacer L; Mzibri ME; Attaleb M
    Urol Oncol; 2024 Dec; 42(12):451.e19-451.e29. PubMed ID: 39147693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Roggisch J; Ecke T; Koch S
    Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
    Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
    Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired TERT promoter mutations stimulate TERT transcription in mantle cell lymphoma.
    Panero J; Alves-Paiva RM; Roisman A; Santana-Lemos BA; Falcão RP; Oliveira G; Martins D; Stanganelli C; Slavutsky I; Calado RT
    Am J Hematol; 2016 May; 91(5):481-5. PubMed ID: 26852175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer.
    Faleiro I; Apolónio JD; Price AJ; De Mello RA; Roberto VP; Tabori U; Castelo-Branco P
    Future Oncol; 2017 Oct; 13(23):2045-2051. PubMed ID: 29019414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
    Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
    J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
    Rachakonda PS; Hosen I; de Verdier PJ; Fallah M; Heidenreich B; Ryk C; Wiklund NP; Steineck G; Schadendorf D; Hemminki K; Kumar R
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17426-31. PubMed ID: 24101484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
    Hosen I; Rachakonda PS; Heidenreich B; de Verdier PJ; Ryk C; Steineck G; Hemminki K; Kumar R
    Int J Cancer; 2015 Oct; 137(7):1621-9. PubMed ID: 25809917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.